BioMarin Pharmaceuticals Inc vs Abbvie Inc.
BMRN vs ABBV — side-by-side comparison from reported financials. BMRN leads 2, ABBV leads 8 of 10 comparable metrics.
BioMarin Pharmaceuticals Inc
BMRN · Healthcare
$54.80-0.16%Mixed
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | BMRN | ABBV |
|---|---|---|
| Price | $54.80 | $276.43 |
| Market cap | $10.6B | $488B |
| Revenue (TTM) | $3.41B | $64.4B |
| Revenue growth | +15.4% | +1.8% |
| Net margin | 2.1% | 9.8% |
| Free cash flow | $738M | $18.2B |
| Net cash (debt) | — | ($56.2B) |
| 1-year price return | +1.8% | +19.8% |
| P/E | 145.4 | 77.4 |
| P/E vs own history (cheap-side %) | 45% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 1% | 96% |
| Altman Z-score | 1.70 | 2.33 |
| CV checks passed | 8 of 10 | 9 of 10 |
| Employees | 3,221 | 57,000 |
Full résumé-style profiles: BMRN CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.